Cancer Drugs Under Development

Publication
Article
OncologyONCOLOGY Vol 9 No 2
Volume 9
Issue 2

According to the Pharmaceutical Research and Manufacturers of America, as of 1993, 124 cancer drugs were in some stage of development at 49 pharmaceutical companies and the National Cancer Institute. The report was based on an NCI survey.

According to the Pharmaceutical Research and Manufacturers ofAmerica, as of 1993, 124 cancer drugs were in some stage of developmentat 49 pharmaceutical companies and the National Cancer Institute.The report was based on an NCI survey. At least 16 of the upcomingcancer drugs are genetically engineered. Since many of these drugsare targeted to more than one type of cancer, 223 research projectsare ongoing.

Recent Videos
Patients with cancer are subjected to fewer radiotherapy-induced toxicities because of newer, more advanced technologies.
Hosts Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, discuss presentations at ESMO 2025 that may impact bladder, kidney, and prostate cancer care.
Mandating additional immunotherapy infusions may help replenish T cells and enhance tumor penetration for solid tumors, including GI malignancies.
A novel cancer database may assist patients determine what clinical trials they are eligible to enroll on and identify the next best steps for treatment.
Receiving information regarding tumor-associated antigens or mutational statuses from biopsies may help treatment selection in GI malignancies.
An easy-to-access database allows one to see a patient’s cancer stage, prior treatment, and survival outcomes in a single place.